-
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
Thursday, February 17, 2022 - 12:23pm | 287Read More...Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC). The data were presented at the American Society of Clinical Oncology (ASCO...
-
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
Tuesday, February 15, 2022 - 10:14am | 280Read More...Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma....
-
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
Tuesday, February 15, 2022 - 10:13am | 263Read More...Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium. The trial is evaluating Fotivda (...
-
Merck's Keytruda Wins European Approval For Post-Surgery Kidney Cancer
Thursday, January 27, 2022 - 10:21am | 221Read More...The European Commission has approved Merck & Co Inc's (NYSE: MRK) Keytruda as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC). Renal cell carcinoma is the most common type of kidney cancer; about nine out of 10 kidney cancer diagnoses are...
-
EMA's CHMP Backs Approval For Merck's Keytruda In Adjuvant Setting For Kidney Cancer
Friday, December 17, 2021 - 10:54am | 198Read More...The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval for Merck & Co Inc's (NYSE: MRK) Keytruda for renal cell carcinoma (RCC). The opinion covers Keytruda as...
-
Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy
Thursday, September 16, 2021 - 2:01pm | 491Read More...Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). Data were presented at the European Society for Medical Oncology Virtual...
-
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
Thursday, September 16, 2021 - 7:49am | 321Read More...Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal cell carcinoma (RCC), regardless of prior nephrectomy (surgical removal of a kidney) status. Data were shared at the...
-
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
Thursday, August 26, 2021 - 7:51am | 266Read More...Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received approval for Cabometyx (cabozantinib) in Japan. The approval covers Cabometyx combined with Bristol-Myers Squibb Co's...
-
Merck's Belzutifan Wins FDA Approval As First Drug For Rare VHL Tumors
Monday, August 16, 2021 - 6:23am | 305Read More...The FDA on Friday approved Merck & Co Inc's (NYSE: MRK) belzutifan for patients with the rare disorder known as von Hippel-Lindau (VHL) disease. VHL is a rare genetic disease that causes tumors and cysts to grow throughout the body. Belzutifan was one of the most...
-
Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer
Thursday, March 11, 2021 - 9:21am | 769Read More...The FDA has finally approved AVEO Pharmaceuticals Inc’s (NASDAQ: AVEO) tivozanib for advanced renal cell carcinoma, nine years after it first submitted its marketing application to the agency. The label covers relapsed or refractory renal cell carcinoma who have received...
-
Exelixis Up 50% After Meteroric METEOR Results
Monday, July 20, 2015 - 9:38am | 287Read More...Shares of Exelixis, Inc. (NASDAQ: EXEL) were surging by more than 50 percent Monday after the company announced positive top-line results from METEOR in which the study met the primary endpoint of significantly improving progress-free survival. Exelixis's positive top-line results stem from...
